TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Trial of the Copper T380 IUD or Oral Levonorgestrel and the Levonorgestrel IUD Initiated With Emergency Contraception
Brief Summary: The purpose of this study is to see how often women who come to a family planning clinic for emergency contraception, the morning after pill, are willing to use either the copper IUD or the levonorgestrel IUD. The investigators will also see if pregnancies occur in those choosing the levonorgestrel IUD and if people continue to use the IUD for 1 year.


Options:
A: Arm Label: Copper IUD; Type: N/A; Interventions: Drug: Copper IUD | Arm Label: Levonorgestrel IUD; Type: N/A; Interventions: Drug: Levonorgestrel IUD | Intervention Type: DRUG; Name: Copper IUD; Assigned to Arm(s): Copper IUD | Intervention Type: DRUG; Name: Levonorgestrel IUD; Assigned to Arm(s): Levonorgestrel IUD
B: Arm Label: CDB-2914; Type: EXPERIMENTAL; Interventions: Drug: CDB-2914 | Arm Label: Levonorgestrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levonorgestrel | Intervention Type: DRUG; Name: CDB-2914; Assigned to Arm(s): CDB-2914 | Intervention Type: DRUG; Name: Levonorgestrel; Assigned to Arm(s): Levonorgestrel
C: Intervention Type: DRUG; Name: CDB-2914; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: levonorgestrel; Assigned to Arm(s): N/A
D: Arm Label: Counseling for LAM; Type: ACTIVE_COMPARATOR; Interventions: Drug: Counseling for LAM+ LNG-EC | Arm Label: Counseling for LAM+ LNG-EC; Type: EXPERIMENTAL; Interventions: Drug: Counseling for LAM+ LNG-EC | Intervention Type: DRUG; Name: Counseling for LAM+ LNG-EC; Assigned to Arm(s): Counseling for LAM, Counseling for LAM+ LNG-EC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Self-management Through Adherence Among Heart Failure Patients
Brief Summary: Non-adherence to self-management behaviors is prevalent and accounts for hospital readmissions in heart failure (HF) patients 65 years of age and older. The mechanism to activate and engage HF patients in managing their own care is uncertain. Yet post-acute care service that is vital to improve HF patients' self-management adherence and HF outcomes is suboptimal in rural hospitals (primarily critical access hospitals). The investigators central hypothesis is that patients with higher activation level will have significantly better self-management adherence. This study will test whether Patient AcTivated Care at Home (PATCH) will improve self-management adherence and health outcome (reduced hospital readmissions), as well as the feasibility to translate the research findings to a home based post-acute care service in rural communities.


Options:
A: Arm Label: STRIP intervention; Type: EXPERIMENTAL; Interventions: Other: STRIP intervention | Arm Label: Control; Type: SHAM_COMPARATOR; Interventions: Other: Control | Intervention Type: OTHER; Name: STRIP intervention; Assigned to Arm(s): STRIP intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Free and convenient medicine access; Type: EXPERIMENTAL; Interventions: Other: Free and convenient medicine access | Arm Label: Usual medicine access; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Free and convenient medicine access; Assigned to Arm(s): Free and convenient medicine access
C: Arm Label: PATCH Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PATCH intervention | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: PATCH intervention; Assigned to Arm(s): PATCH Intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care
D: Arm Label: regular, pharmacy-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Regular, pharmacy based intervention | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Regular, pharmacy based intervention; Assigned to Arm(s): regular, pharmacy-based intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Promoting Self-management Through Adherence Among Heart Failure Patients
Brief Summary: Non-adherence to self-management behaviors is prevalent and accounts for hospital readmissions in heart failure (HF) patients 65 years of age and older. The mechanism to activate and engage HF patients in managing their own care is uncertain. Yet post-acute care service that is vital to improve HF patients' self-management adherence and HF outcomes is suboptimal in rural hospitals (primarily critical access hospitals). The investigators central hypothesis is that patients with higher activation level will have significantly better self-management adherence. This study will test whether Patient AcTivated Care at Home (PATCH) will improve self-management adherence and health outcome (reduced hospital readmissions), as well as the feasibility to translate the research findings to a home based post-acute care service in rural communities.


Options:
A: Arm Label: Telerehabilitation programme; Type: EXPERIMENTAL; Interventions: Device: Telerehabilitation programme | Arm Label: Control group traditional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telerehabilitation programme; Assigned to Arm(s): Telerehabilitation programme
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
C: Arm Label: PATCH Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: PATCH intervention | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: PATCH intervention; Assigned to Arm(s): PATCH Intervention | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual Care
D: Arm Label: OPTICARE-A; Type: EXPERIMENTAL; Interventions: Other: rehabilitation+telephonic coaching | Arm Label: OPTICARE-B; Type: ACTIVE_COMPARATOR; Interventions: Other: OPTICARE-B | Arm Label: OPTICARE-C; Type: EXPERIMENTAL; Interventions: Other: OPTICARE-C | Intervention Type: OTHER; Name: rehabilitation+telephonic coaching; Assigned to Arm(s): OPTICARE-A | Intervention Type: OTHER; Name: OPTICARE-B; Assigned to Arm(s): OPTICARE-B | Intervention Type: OTHER; Name: OPTICARE-C; Assigned to Arm(s): OPTICARE-C

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect Evaluation of Individual Placement and Support (IPS)
Brief Summary: Roughly one third of disability pensions issued in Norway are classified as mental and behavioral disorders. The proposed study aims to evaluate the effect of an innovative intervention for returning people with moderate to severe mental health disorders to work: Individual Placement and Support (IPS).


Options:
A: Arm Label: Individual Placement and Support-vocational rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support-vocational rehabilitation | Arm Label: Vocational rehabilitation available at study site; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Vocational rehabilitation available | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support-vocational rehabilitation; Assigned to Arm(s): Individual Placement and Support-vocational rehabilitation | Intervention Type: BEHAVIORAL; Name: Vocational rehabilitation available; Assigned to Arm(s): Vocational rehabilitation available at study site
B: Arm Label: Individual Placement and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support | Arm Label: Ordinary employment schemes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary employment schemes | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support; Assigned to Arm(s): Individual Placement and Support | Intervention Type: BEHAVIORAL; Name: Ordinary employment schemes; Assigned to Arm(s): Ordinary employment schemes
C: Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT, Behavioral: EAP | Arm Label: TAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EAP | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT | Intervention Type: BEHAVIORAL; Name: EAP; Assigned to Arm(s): CBT, TAU
D: Arm Label: duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Arm Label: fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: paroxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine | Arm Label: sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: sertraline | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): duloxetine | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): paroxetine | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): sertraline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect Evaluation of Individual Placement and Support (IPS)
Brief Summary: Roughly one third of disability pensions issued in Norway are classified as mental and behavioral disorders. The proposed study aims to evaluate the effect of an innovative intervention for returning people with moderate to severe mental health disorders to work: Individual Placement and Support (IPS).


Options:
A: Intervention Type: PROCEDURE; Name: Individual placement and support (vocational rehabilitation); Assigned to Arm(s): N/A
B: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Computer-Based Cognitive Enhancement Training Program, Behavioral: Work Therapy Program | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Work Therapy Program | Intervention Type: BEHAVIORAL; Name: Computer-Based Cognitive Enhancement Training Program; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Work Therapy Program; Assigned to Arm(s): 1, 2
D: Arm Label: Individual Placement and Support; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Placement and Support | Arm Label: Ordinary employment schemes; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ordinary employment schemes | Intervention Type: BEHAVIORAL; Name: Individual Placement and Support; Assigned to Arm(s): Individual Placement and Support | Intervention Type: BEHAVIORAL; Name: Ordinary employment schemes; Assigned to Arm(s): Ordinary employment schemes

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Can Intermittent Fasting Mimic the Metabolic and Cardiovascular and Anti-aging Effects of Calorie Restriction?
Brief Summary: The purpose of Intermittent Fasting study is to investigate whether intermittent fasting could decrease the chronic inflammation levels in overweight/obese people.


Options:
A: Arm Label: Control group; Type: OTHER; Interventions: Other: control group | Arm Label: Intermittent Fasting group; Type: EXPERIMENTAL; Interventions: Other: Intermittent Fasting group | Intervention Type: OTHER; Name: Intermittent Fasting group; Assigned to Arm(s): Intermittent Fasting group | Intervention Type: OTHER; Name: control group; Assigned to Arm(s): Control group
B: Arm Label: Grazing; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Grazing | Arm Label: Time-restricted feeding (early eating); Type: EXPERIMENTAL; Interventions: Behavioral: Time-restricted feeding (early eating) | Intervention Type: BEHAVIORAL; Name: Grazing; Assigned to Arm(s): Grazing | Intervention Type: BEHAVIORAL; Name: Time-restricted feeding (early eating); Assigned to Arm(s): Time-restricted feeding (early eating)
C: Arm Label: Early Time Restricted Feeding; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restricted Feeding | Arm Label: Mid-day Time Restricted Feeding; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restricted Feeding | Intervention Type: BEHAVIORAL; Name: Time Restricted Feeding; Assigned to Arm(s): Early Time Restricted Feeding, Mid-day Time Restricted Feeding
D: Arm Label: Time restricted feeding; Type: EXPERIMENTAL; Interventions: Other: Time restricted feeding | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Time restricted feeding; Assigned to Arm(s): Time restricted feeding

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ASP3550 Phase III Study - An Open-Label, Active-Controlled, Parallel-Arm Study, Comparing ASP3550 With Goserelin Acetate in Patients With Prostate Cancer -
Brief Summary: To compare the efficacy and safety of ASP3550 to goserelin acetate in patients with prostate cancer.


Options:
A: Arm Label: Degarelix 240 mg/80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Goserelin (3.6 mg) + bicalutamide (50 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin, Drug: Bicalutamide | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix 240 mg/80 mg | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg) | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg)
B: Arm Label: ASP3550 PART 1 and PART 2; Type: EXPERIMENTAL; Interventions: Drug: degarelix | Arm Label: Goserelin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin | Intervention Type: DRUG; Name: degarelix; Assigned to Arm(s): ASP3550 PART 1 and PART 2 | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin
C: Arm Label: Degarelix; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Degarelix + Casodex; Type: EXPERIMENTAL; Interventions: Drug: Degarelix, Drug: Casodex | Arm Label: LHRH Agonist + Casodex; Type: ACTIVE_COMPARATOR; Interventions: Drug: Casodex, Drug: LHRH Agonist | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix, Degarelix + Casodex | Intervention Type: DRUG; Name: Casodex; Assigned to Arm(s): Degarelix + Casodex, LHRH Agonist + Casodex | Intervention Type: DRUG; Name: LHRH Agonist; Assigned to Arm(s): LHRH Agonist + Casodex
D: Arm Label: Degarelix 240 mg/80 mg; Type: EXPERIMENTAL; Interventions: Drug: Degarelix | Arm Label: Goserelin (3.6 mg) + bicalutamide (50 mg); Type: ACTIVE_COMPARATOR; Interventions: Drug: Goserelin, Drug: Bicalutamide | Intervention Type: DRUG; Name: Degarelix; Assigned to Arm(s): Degarelix 240 mg/80 mg | Intervention Type: DRUG; Name: Goserelin; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg) | Intervention Type: DRUG; Name: Bicalutamide; Assigned to Arm(s): Goserelin (3.6 mg) + bicalutamide (50 mg)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, Parallel Groups, Placebo-controlled, Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-
Brief Summary: This study is to evaluate the safety and the dose-response of ASP1517 in the treatment of anemia in non-dialysis Chronic Kidney Disease (CKD) patients when ASP1517 is applied intermittently.


Options:
A: Arm Label: Darbepoetin Alfa Injection; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa | Arm Label: Desidustat oral tablet; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desidustat Oral Tablet | Intervention Type: DRUG; Name: Desidustat Oral Tablet; Assigned to Arm(s): Desidustat oral tablet | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Darbepoetin Alfa Injection
B: Arm Label: Vadadustat, Dose 1; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat, Dose 2; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Vadadustat, Dose 3; Type: EXPERIMENTAL; Interventions: Drug: Vadadustat | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vadadustat; Assigned to Arm(s): Vadadustat, Dose 1, Vadadustat, Dose 2, Vadadustat, Dose 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: FG-4592; Type: EXPERIMENTAL; Interventions: Drug: FG-4592 | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: FG-4592; Assigned to Arm(s): FG-4592 | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa
D: Arm Label: ASP1517 low dose group; Type: EXPERIMENTAL; Interventions: Drug: ASP1517 | Arm Label: ASP1517 middle dose group; Type: EXPERIMENTAL; Interventions: Drug: ASP1517 | Arm Label: ASP1517 high dose group; Type: EXPERIMENTAL; Interventions: Drug: ASP1517 | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ASP1517; Assigned to Arm(s): ASP1517 high dose group, ASP1517 low dose group, ASP1517 middle dose group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: In-hospital and Post-discharge Training of Older Medical Patients
Brief Summary: The project aims to investigate the clinical value of simple strength training during hospitalization and after discharge as part of an enhanced recovery programme for acutely admitted older medical patients, in order to prevent mobility decline following acute hospitalization.

Note 11/23/16: As noted in the protocol (doi: 10.1186/s13063-016-1309-1) we have obtained funding and ethical approval (H-2-2012-115/09-12-2016) to extend the study to achieve sufficient power to look more deeply into our secondary outcomes. This will constitute a secondary part of the trial (started Nov. 2016). The primary trial report will include data for the pre-specified sample size for which the last patient was assessed Oct. 2016. Hence, the primary completion date for part 1 was April 2016 and the study completion date for part 1 was Oct 2016. The trial status is still "recruiting" although this applies to part 2 of the study.


Options:
A: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control group
B: Arm Label: Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: High-protein diet and resistance training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: High-protein diet and resistance training; Assigned to Arm(s): Intervention
C: Arm Label: Strength training; Type: EXPERIMENTAL; Interventions: Other: Strength training | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Strength training; Assigned to Arm(s): Strength training
D: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy program | Arm Label: Control group; Type: OTHER; Interventions: Drug: cephalosporin with or without erythromycin | Intervention Type: DRUG; Name: cephalosporin with or without erythromycin; Assigned to Arm(s): Control group | Intervention Type: OTHER; Name: Physiotherapy program; Assigned to Arm(s): Experimental group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Performance Diagnosis of Hemodynamic Parameters of Preload Dependence in ARDS Patients During Prone Position
Brief Summary: Preload dependence assessment is difficult during prone position, and to date, no hemodynamic parameters have been validated to rationalize fluid loading in that position. This study aims to validate several hemodynamic parameters, using continuous cardiac output by pulse contour analysis and transpulmonary thermodilution.


Options:
A: Arm Label: Repetitive recruitment with PEEP; Type: EXPERIMENTAL; Interventions: Procedure: Repetitive recruitment with PEEP | Arm Label: One recruitment with PEEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: One recruitment with PEEP | Intervention Type: PROCEDURE; Name: Repetitive recruitment with PEEP; Assigned to Arm(s): Repetitive recruitment with PEEP | Intervention Type: PROCEDURE; Name: One recruitment with PEEP; Assigned to Arm(s): One recruitment with PEEP
B: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Procedure: Trendelenburg position | Intervention Type: PROCEDURE; Name: Trendelenburg position; Assigned to Arm(s): Single arm
C: Arm Label: Semirecumbent position; Type: ACTIVE_COMPARATOR; Interventions: Other: lateral-Trendelenburg position | Arm Label: lateral-Trendelenburg position; Type: EXPERIMENTAL; Interventions: Other: lateral-Trendelenburg position | Intervention Type: OTHER; Name: lateral-Trendelenburg position; Assigned to Arm(s): Semirecumbent position, lateral-Trendelenburg position
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial
Brief Summary: To test if multimodal analgesia with different analgesic medication offer better pain relief, lesser side effects and is safe compared to conventionel opiod analgesia after cardiac surgery.


Options:
A: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
B: Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Gabapentin, Drug: Paracetamol | Arm Label: Morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Morphine, Drug: Paracetamol | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Multimodal | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Morphine, Multimodal
C: Arm Label: Study (CytoSorb); Type: EXPERIMENTAL; Interventions: Device: CytoSorb | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Corticosteroid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone | Intervention Type: DEVICE; Name: CytoSorb; Assigned to Arm(s): Study (CytoSorb) | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Corticosteroid
D: Arm Label: Sevoflurane Group; Type: N/A; Interventions: Drug: Sevoflurane | Arm Label: Not Sevoflurane Group; Type: N/A; Interventions: N/A | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Sevoflurane Group

Answer: B